Evidence map›Paper›PMID 25189144›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2014

In-vivo monitoring of erythropoietin treatment after myocardial infarction in mice with [⁶⁸Ga]Annexin A5 and [¹⁸F]FDG PET.

Andrei Todica, Mathias J Zacherl, Hao Wang, Guido Böning, Nathalie L Jansen, Carmen Wängler, Peter Bartenstein, Michael C Kreissl, Marcus Hacker, Stefan Brunner and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Derivation of a respiration trigger signal in small animal list-mode PET based on respiration-induced variations of the ECG signal.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrei TodicaDepartment of Nuclear Medicine, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
Mathias J Zacherl
Hao Wang
Guido Böning
Nathalie L Jansen
Carmen Wängler
Peter Bartenstein
Michael C Kreissl
Marcus Hacker
Stefan Brunner
Sebastian Lehner

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral studies substantiate the cardioprotective effects of erythropoietin (EPO). Our goal was to quantify the effects of EPO treatment on the early expression of the apoptosis marker phosphatidylserine as well as on the left ventricular volumes and function by means of small animal PET. METHODS AND

resultsMyocardial infarction (MI) was induced in C57BL/6 mice. Animals were assigned to saline or EPO groups and underwent Annexin PET (day 2) and gated FDG PET (days 6 and 30). Annexin uptake was significantly higher in the infarction than in remote myocardium, with no differences between treatment groups. Infarct size showed a slight decrease in the EPO group and a slight increase in the controls, which did not reach statistical significance. Follow-up analyses revealed a significant increase of end-diastolic and end-systolic volumes in the EPO group, in which a stable left ventricular ejection fraction (LVEF) was maintained.

conclusionWe find that deleterious effects of EPO can outweigh cardioprotective effects. The present EPO treatment did not significantly reduce apoptosis after MI, but seemingly provoked significant myocardial dilation while maintaining a stable LVEF. Molecular mechanisms of EPO treatment may need further elucidation to optimize therapy regimens.

Indexed as

Annexin A5Fluorodeoxyglucose F18AnimalsCardiotonic AgentsDrug MonitoringErythropoietinMaleMiceMice, Inbred C57BLMyocardial InfarctionPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsSensitivity and SpecificityTreatment OutcomeAnnexin A5Cardiotonic AgentsErythropoietinFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.